BNT162b2 mRNA COVID-19 Vaccination (BNTCV) in Patients (Pts) Having Hematological Malignancies (HM): Early tolerance with telemedicine application connecting and antibody anti-Spik...

por Rossi, Jean-Francois, Bonnet, Emmanuel, Velensek, Marion, Wisniewski, Emma, Heraud, Sophie, Boustany, Rania, David, Celeste, Dinet, Jerome, Sicard, Roland, Daures, Jean Pierre, Bonifacy, Marion, Mousset, Lysiane, Goffard, Emmanuel
Publicado 2021

Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study

por Rossi, Jean-François, Bonnet, Emmanuel, Castelli, Christel, Velensek, Marion, Wisniewski, Emma, Heraud, Sophie, Boustany, Rania, David, Céleste, Dinet, Jérôme, Sicard, Roland, Daures, Jean-Pierre, Bonifacy, Marion, Mousset, Lysiane, Goffart, Emmanuel
Publicado 2023

REAL-LIFE STUDY OF BIO-CLINICAL FOLLOW-UP AFTER BNT162b2 mRNA COVID-19 (BNTCV) VACCINATION IN 235 PATIENTS (PTS) INCLUDING 225 WITH HEMATOLOGICAL MALIGNANCIES (HM).

por Rossi, Jean-François, Bonnet, Emmanuel, Velensek, Marion, Wisniewski, Emma, Heraud, Sophie, Boustany, Rania, David, Céleste, Dinet, Jérôme, Sicard, Roland, Daures, Jean-Pierre, Bonifacy, Marion, Mousset, Lysiane, Castelli, Christel, Goffart, Emmanuel
Publicado 2022